Clinical Trials Browser

Phase 2 × NSCLC × surufatinib × Clear all

NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Phase 2 Not yet recruiting

NSCLC